A 70-year-old Caucasian male with a past medical history of hypertension, hyperlipidemia, atherosclerotic cardiovascular disease (ASCVD) manifesting as two myocardial infarctions requiring three stent placements, gastroesophageal reflux disease (GERD) and obstructive sleep apnea (OSA) was seen in the endocrine clinic for management of his hyperlipidemia. He had a positive family history for hyperlipidemia in both his mother and sister. The latter having premature ASCVD since she had a myocardial infarction in her forties. He denied smoking cigarettes, ingesting alcohol and any substance abuse. In 1993, the patient was found to have elevated lipids and was placed on different cholesterol lowering agents over the years including fluvastatin, lovastatin, pravastatin, atorvastatin, niacin, fenofibrate, ezetimibe and colestipol. He could not tolerate statin therapy because of myalgias and experienced gastro-intestinal side effects with both niacin and colestipol. Following his initial evaluation at the endocrine clinic and his high risk for ASCVD, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy was considered based on the most recent AHA/ACC Multi-society Cholesterol Guidelines.
1He did not have tendon xanthoma or diminished pulses. His-lipid profile at this visit revealed a total Cholesterol 330 mg/dl (all reference ranges provided in parentheses, <200 mg/dl); Triglyceride 121 mg/dl (<150 mg/dl); LDL-C-247 mg/dl (<100 mg/dl); HDL-C-59 mg/dl (>40 mg/dl). Other pertinent laboratories revealed a creatinine 1.26 mg/dl (0.5–1.1); albumin 4.5 g/dl (3.3–4.8), TSH-1.53 uIU/mL (0.34–5.60), HBAIC 5.9% (<6.5%).His-urine was negative for protein. Alirocumab was recommended by the VA pharmacy and was initiated at a dose of 75 mg subcutaneous injection every 2 weeks in addition to ezetimibe.
- Virani S.S.
- Akeroyd J.M.
- Smith S.C.
- et al.
Very high-risk ASCVD and eligibility for nonstatin therapies based on the 2018 AHA/ACC cholesterol guidelines.
J Am Coll Cardiol. 2019; 74: 712-714
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of the Medical Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Very high-risk ASCVD and eligibility for nonstatin therapies based on the 2018 AHA/ACC cholesterol guidelines.J Am Coll Cardiol. 2019; 74: 712-714
- Atopic dermatitis-like rash during evolocumab treatment of familial hypercholesterolemia.J Nippon Med Sch. 2019; 86: 187-190
- Maculopapular exanthema after the second dose of evolocumab.Cureus. 2021; 13
Published online: December 22, 2022
Accepted: December 19, 2022
Received: September 26, 2022
Published by Elsevier Inc. on behalf of Southern Society for Clinical Investigation.